Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szu-Chun Yang

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Respirology (Carlton, Vic.)|August 16, 2023
Letter from TaiwanSzu-Chun Yang, Jung-Der Wang
Scientific Reports|June 10, 2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world dataSzu-Chun Yang, Jung-Der Wang, Shi-Yi Wang
Clinicoeconomics and Outcomes Research : CEOR|October 24, 2024
Estimating Costs Associated with Adverse Events in Patients with Advanced Lung CancerChien-Yu Lin, Tzu-I Wu, Szu-Chun Yang
BMJ Open|March 18, 2019
Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series studyJason C Hsu, Chen-Fang Wei, Szu-Chun Yang
Journal of General Internal Medicine|January 20, 2021
Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008-2016Szu-Chun Yang, Cary Gross, Jung-Der Wang, et al.
Respirology (Carlton, Vic.)|May 23, 2013
Positive blood culture is not associated with increased mortality in patients with sepsis-induced acute respiratory distress syndromeSzu-Chun Yang, Kuang-Ming Liao, Chang-Wen Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2022
Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence AreasSzu-Chun Yang, Yi-Chen Yeh, Yi-Lin Chen, et al.
Frontiers in Oncology|June 7, 2022
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung AdenocarcinomaSzu-Chun Yang, Chien-Chung Lin, Yi-Lin Chen, et al.
Cancer Medicine|January 19, 2023
Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancerSzu-Chun Yang, Huang-Tz Ou, Wu-Chou Su, et al.
JTO Clinical and Research Reports|November 14, 2025
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Limited-Stage SCLCSheng-Han Tsai, Jui-Hung Tsai, Li-Jun Chen, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Respirology (Carlton, Vic.)|August 16, 2023
Letter from TaiwanSzu-Chun Yang, Jung-Der Wang
Scientific Reports|June 10, 2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world dataSzu-Chun Yang, Jung-Der Wang, Shi-Yi Wang
Clinicoeconomics and Outcomes Research : CEOR|October 24, 2024
Estimating Costs Associated with Adverse Events in Patients with Advanced Lung CancerChien-Yu Lin, Tzu-I Wu, Szu-Chun Yang
BMJ Open|March 18, 2019
Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series studyJason C Hsu, Chen-Fang Wei, Szu-Chun Yang
Journal of General Internal Medicine|January 20, 2021
Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008-2016Szu-Chun Yang, Cary Gross, Jung-Der Wang, et al.
Respirology (Carlton, Vic.)|May 23, 2013
Positive blood culture is not associated with increased mortality in patients with sepsis-induced acute respiratory distress syndromeSzu-Chun Yang, Kuang-Ming Liao, Chang-Wen Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2022
Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence AreasSzu-Chun Yang, Yi-Chen Yeh, Yi-Lin Chen, et al.
Frontiers in Oncology|June 7, 2022
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung AdenocarcinomaSzu-Chun Yang, Chien-Chung Lin, Yi-Lin Chen, et al.
Cancer Medicine|January 19, 2023
Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancerSzu-Chun Yang, Huang-Tz Ou, Wu-Chou Su, et al.
JTO Clinical and Research Reports|November 14, 2025
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Limited-Stage SCLCSheng-Han Tsai, Jui-Hung Tsai, Li-Jun Chen, et al.
Pageof 6